10x Genomics (NASDAQ:TXG) Receives “Sell (E+)” Rating from Weiss Ratings

Weiss Ratings restated their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG) in a research report released on Saturday,Weiss Ratings reports.

A number of other research firms also recently weighed in on TXG. Stephens restated an “overweight” rating and set a $30.00 price target on shares of 10x Genomics in a research report on Thursday, October 10th. Citigroup decreased their price objective on 10x Genomics from $35.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday, October 30th. Morgan Stanley cut their target price on 10x Genomics from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, January 13th. Barclays decreased their price target on shares of 10x Genomics from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Finally, UBS Group lowered their price target on shares of 10x Genomics from $25.00 to $20.00 and set a “neutral” rating for the company in a research note on Wednesday, October 30th. One analyst has rated the stock with a sell rating, seven have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $23.86.

10x Genomics Trading Down 0.1 %

Shares of TXG stock traded down $0.01 during trading hours on Friday, reaching $15.08. The stock had a trading volume of 1,324,480 shares, compared to its average volume of 1,475,648. The stock’s fifty day simple moving average is $14.96 and its 200 day simple moving average is $17.95. The firm has a market capitalization of $1.83 billion, a PE ratio of -9.86 and a beta of 1.83. 10x Genomics has a 12 month low of $12.95 and a 12 month high of $51.22.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.04. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The company had revenue of $151.65 million for the quarter, compared to the consensus estimate of $158.84 million. During the same quarter last year, the business posted ($0.51) earnings per share. The firm’s revenue was down 1.3% compared to the same quarter last year. As a group, equities research analysts anticipate that 10x Genomics will post -1.43 EPS for the current fiscal year.

Institutional Trading of 10x Genomics

A number of hedge funds have recently made changes to their positions in the stock. State of New Jersey Common Pension Fund D boosted its stake in 10x Genomics by 41.7% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 84,118 shares of the company’s stock worth $1,636,000 after purchasing an additional 24,761 shares in the last quarter. Federated Hermes Inc. bought a new position in shares of 10x Genomics in the second quarter worth approximately $136,000. Renaissance Technologies LLC grew its holdings in shares of 10x Genomics by 301.1% during the second quarter. Renaissance Technologies LLC now owns 210,200 shares of the company’s stock valued at $4,088,000 after buying an additional 157,800 shares during the last quarter. Hsbc Holdings PLC bought a new stake in shares of 10x Genomics during the second quarter valued at approximately $1,797,000. Finally, Benjamin F. Edwards & Company Inc. raised its holdings in 10x Genomics by 10,124.9% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 44,785 shares of the company’s stock worth $871,000 after acquiring an additional 44,347 shares during the last quarter. 84.68% of the stock is owned by institutional investors.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.